More answers like this
GPT-5Nov 7, 2026openai/gpt-5-2025-08-07

Should AI development be paused or restricted?

Short answer: A blanket pause on all AI work isn’t practical or desirable. But targeted, enforceable pauses and restrictions on specific high‑risk capabilities—and stronger governance for “frontier” systems—are warranted while allowing most beneficial AI R&D to continue.

A practical way to think about it

•Split the question by activity: training new frontier models, deploying models, and open‑sourcing weights. Different rules should apply to each.
•Regulate by capability and risk, not just by model size or brand. Focus on what the system can actually do, and who can access it.

When a pause makes sense

•Clear tripwires for temporary moratoria on training or release should trigger if evals show any of the following:
•Material assistance in designing or executing biological, chemical, or radiological harm.
•Offensive cyber capability beyond widely available tools (e.g., automated discovery/exploitation of serious vulnerabilities).
•Persuasive manipulation at population scale (e.g., fully automated targeted influence operations).
•Autonomous agent behavior that can plan, execute, and self‑replicate across systems without strong containment.
•Pauses should be time‑bound, tied to specific safety milestones (evals, mitigations, audits), and narrowly scoped to the risky capability or model family.

Restrictions that should be adopted now

•Licensing for frontier training runs: Require a license when compute or spend crosses a regulator‑set threshold. Conditions: documented risk management plans, third‑party red‑teaming, incident response, and a “shutdown” plan if evals fail.
•Compute tracking and reporting: Require cloud and chip vendors to log large training runs to a regulator to enable oversight without chilling routine research.
•Mandatory capability and safety evaluations: Standardized, independent tests before and after training (and after major updates) for bio, cyber, manipulation, and autonomy risks; publish summaries.
•Deployment safeguards:
•Progressive release (staged access, tight rate limits early on).
•Tool and data gating for dangerous domains (e.g., restrict code‑exec tools, vuln scanners, lab protocols).
•Identity and use‑case verification for high‑risk API features; audit logs and anomaly detection.
•Content provenance and watermarking to curb deceptive use; robust abuse reporting and takedown.
•Weight release policy: No open release of weights for models that substantially enable the tripwire risks above. Use gated access, evals, and researcher agreements instead. Open release is fine for clearly low‑risk models.
•Corporate governance: Independent safety boards with real veto power; model registry, post‑incident reporting, and regular external audits; link executive comp to safety metrics.
•Liability and enforcement: Product‑safety style obligations for deployers; penalties for negligent releases; safe harbors for good‑faith researchers who disclose vulnerabilities.

What should not be paused

•Safety, alignment, and interpretability research; robustness and monitoring tools; privacy‑preserving ML; applications in low‑risk domains (accessibility, basic productivity, education aids), provided they follow standard data‑protection and consumer‑protection rules.

International coordination to avoid a race to the bottom

•Harmonize eval standards and reporting; establish joint red‑team exercises.
•Maintain export controls and traceability for cutting‑edge AI chips while enabling legitimate research collaboration.
•Explore “non‑proliferation” style agreements for the most dangerous capabilities.

How to decide in practice (simple rubric)

•Risk = Capability severity × Exposure × Intent feasibility.
•If any dimension is high and mitigations are weak, restrict or pause.
•Re‑assess after mitigations (sandboxing, gating, fine‑tuning limits, monitoring) and independent audits.

If you want, tell me the context you care about most—open‑source models, corporate labs, government policy, or a specific domain like healthcare or education—and I’ll tailor concrete steps for that setting.

Citations (0)